

MEDIA STATEMENT

PHILOGEN SPA ANNOUNCES PARTICIPATION TO THE “5TH HEIDELBERG FORUM FOR YOUNG LIFE SCIENTISTS (HFYLS)”, JUNE 8-9, 2017, HEIDELBERG, GERMANY

[Philogen S.p.A.](#) and its fully owned subsidiary [Philochem AG](#), announce their participation to the “5th Heidelberg Forum for Young Life Scientists” that will take place at the German Cancer Research Center in Heidelberg from June 8 to June 9, 2017.

The meeting, organized by PhD students from different research institutes, research networks and graduate schools of Heidelberg and Mannheim, aims to provide new insights into a broad range of current research topics.

Prof. Dr. Dario Neri, Swiss Federal Institute of Technology Zurich, co-founder and Chairman of the scientific advisory board of Philogen, will give a lecture on Friday, June 9 in the “[Translational Cancer Research – Aiming for the Achilles’ Heel](#)” section.

For additional news and press release topics, visit: <http://www.philogen.com/en/news/>

About the Philogen group

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com
